Valvular & structural heart disease

Management of patients with transvalvular right ventricular leads undergoing transcatheter tricuspid valve interventions: a scientific statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC endorsed by the Heart Rhythm Society, the Asian Pacific Heart Rhythm Society and the Canadian Heart Rhythm Society

EuropacePublished Scientific statement

Scope

As issued by the authors

Reviews the scientific evidence to inform Heart Team discussions on managing patients with a PPM or implantable cardioverter-defibrillator (ICD) who are scheduled for or have undergone transcatheter tricuspid valve intervention (TTVI); up to one-third of TTVI referrals have a transvalvular lead, with risk of lead jailing or damage

Original publication

Management of patients with transvalvular right ventricular leads undergoing transcatheter tricuspid valve interventions: a scientific statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC endorsed by the Heart Rhythm Society, the Asian Pacific Heart Rhythm Society and the Canadian Heart Rhythm Society. Europace. Published 31 March 2025. doi:10.1093/europace/euaf061

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.